BioCryst shareholders approve 7M-share increase to Stock Incentive Plan

BIOCRYST PHARMACEUTICALS INC

Stockholders approved amendment increasing authorized shares by 7,000,000 to 70,090,000 total under the plan.
Directors re-elected: Nancy J. Hutson, Vincent J. Milano, A. Machelle Sanders; broker non-votes 26,962,524.
Ernst & Young ratified as FY 2024 auditor (167,496,029 for); advisory exec-comp resolution passed (138,402,008 for).
Incentive Plan Proposal passed with 101,846,368 for, 43,055,807 against; plan now includes 12-month minimum vesting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.